Literature DB >> 25424811

Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergy.

Paola Lorena Smaldini1, Andrés Esteban Ibañez, Carlos Alberto Fossati, Juliana Cassataro, Guillermo Horacio Docena.   

Abstract

Food allergies are increasingly common disorders and no therapeutic strategies are yet approved. The unlipidated Omp16 (U-Omp16) is the outer membrane protein of 16 kDa from B. abortus and possesses a mucosal adjuvant property. In this study, we aimed to examine the U-Omp16 capacity to abrogate an allergen-specific Th2 immune response when it is administered as an oral adjuvant in a mouse model of food allergy.   Balb/c mice were sensitized with cholera toxin and cow's milk proteins (CMP) by gavage and simultaneously treated with U-Omp16 and CMP. Oral challenge with CMP was performed to evaluate the allergic status of mice. Symptoms, local (small bowel cytokine and transcription factor gene expression) and systemic (specific isotypes and spleen cell-secreted cytokines) parameters, and skin tests were done to evaluate the immune response. We found that the oral administration of U-Omp16 with CMP during sensitization dampened the allergic symptoms, with negativization of immediate skin test and increased skin DTH response. Serum specific IgE and IL-5 were inhibited and a Th1 response was promoted (specific IgG2a antibodies and CMP-induced IFN-γ secretion). We found at the mucosal site an inhibition of the gene expression corresponding to IL-13 and Gata-3, with an induction of IFN-γ and T-bet. These results indicated that the oral administration of U-Omp16 significantly controlled the allergic response in sensitized mice with a shift of the balance of Th1- and Th2-T cells toward Th1 predominance. These findings suggest that U-Omp16 may be useful as a Th1-directing adjuvant in an oral vaccine.

Entities:  

Keywords:  IgE; U-Omp16; immunomodulation; intestinal mucosa; milk allergy; oral adjuvant

Mesh:

Substances:

Year:  2014        PMID: 25424811      PMCID: PMC4186055          DOI: 10.4161/hv.28845

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

Review 1.  Family size, infection and atopy: the first decade of the "hygiene hypothesis".

Authors:  D P Strachan
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Dendritic cells from mycobacteria-infected mice inhibits established allergic airway inflammatory responses to ragweed via IL-10- and IL-12-secreting mechanisms.

Authors:  Laura Bilenki; Xiaoling Gao; Shuhe Wang; Jie Yang; Yijun Fan; Xiaobing Han; Hongyu Qiu; Xi Yang
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

3.  Hay fever, hygiene, and household size.

Authors:  D P Strachan
Journal:  BMJ       Date:  1989-11-18

Review 4.  Adjuvants and vector systems for allergy vaccines.

Authors:  Philippe Moingeon; Vincent Lombardi; Nathalie Saint-Lu; Sophie Tourdot; Véronique Bodo; Laurent Mascarell
Journal:  Immunol Allergy Clin North Am       Date:  2011-05       Impact factor: 3.479

Review 5.  The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?

Authors:  Sergio Romagnani
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

6.  Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.

Authors:  M M Levine; R E Black; M L Clements; C Lanata; S Sears; T Honda; C R Young; R A Finkelstein
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

7.  The prevalence of food allergy: a meta-analysis.

Authors:  Roberto J Rona; Thomas Keil; Colin Summers; David Gislason; Laurian Zuidmeer; Eva Sodergren; Sigurveig T Sigurdardottir; Titia Lindner; Klaus Goldhahn; Jorgen Dahlstrom; Doreen McBride; Charlotte Madsen
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

8.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

Authors:  Margot Mutsch; Weigong Zhou; Philip Rhodes; Matthias Bopp; Robert T Chen; Thomas Linder; Christian Spyr; Robert Steffen
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

9.  Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization.

Authors:  R Glueck
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

10.  Unlipidated outer membrane protein Omp16 (U-Omp16) from Brucella spp. as nasal adjuvant induces a Th1 immune response and modulates the Th2 allergic response to cow's milk proteins.

Authors:  Andrés E Ibañez; Paola Smaldini; Lorena M Coria; María V Delpino; Lucila G G Pacífico; Sergio C Oliveira; Gabriela S Risso; Karina A Pasquevich; Carlos Alberto Fossati; Guillermo H Giambartolomei; Guillermo H Docena; Juliana Cassataro
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more
  1 in total

1.  Orally-Induced Intestinal CD4+ CD25+ FoxP3+ Treg Controlled Undesired Responses towards Oral Antigens and Effectively Dampened Food Allergic Reactions.

Authors:  Paola Lorena Smaldini; María Lucía Orsini Delgado; Carlos Alberto Fossati; Guillermo Horacio Docena
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.